Open AccessHistone deacetylase inhibitor MS-275 alone or combined with bortezomib or sorafenib exhibits strong antiproliferative action in human cholangiocarcinoma cells
Author(s) -
Viola Baradari,
Michael Höpfner,
Alexander Huether,
Detlef Schuppan,
Hans Scherübl
Publication year - 2007
Publication title -
world journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.427
H-Index - 155
eISSN - 2219-2840
pISSN - 1007-9327
DOI - 10.3748/wjg.v13.i33.4458
Subject(s) - bortezomib , sorafenib , cancer research , histone deacetylase inhibitor , cell cycle , apoptosis , cell growth , proteasome inhibitor , chemistry , gemcitabine , biology , pharmacology , histone deacetylase , cancer , biochemistry , histone , hepatocellular carcinoma , immunology , multiple myeloma , genetics , gene
To investigate the antiproliferative effect of the histone deacetylase (HDAC) inhibitor MS-275 on cholangiocarcinoma cells alone and in combination with conventional cytostatic drugs (gemcitabine or doxorubicin) or the novel anticancer agents sorafenib or bortezomib.